MGLL was significantly upregulated in diffuse large B cell lymphoma (DLBC), acute myeloid leukemia (LAML), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), and stomach adenocarcinoma (STAD), while it was downregulated in breast invasive carcinoma (BRCA), head and neck squamous cell carcinoma (HNSC), lung squamous cell carcinoma (LUSC), bladder urothelial carcinoma (BLCA), and skin cutaneous melanoma (SKCM). Here, MGLL is linked to acute myeloid leukemia.